Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.26 USD | -3.74% | -6.78% | -28.28% |
01:51pm | Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating | MT |
May. 07 | Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.28% | 5.32B | |
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-16.05% | 31.87B | |
+53.68% | 24.52B | |
-14.29% | 15.68B | |
-6.52% | 12.34B | |
-39.65% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating